- Title
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
- Creators
- Jordan R Barrett - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKSandra Belij-Rammerstorfer - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKChristina Dold - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKK Ewer - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKPedro M Folegatti - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKCiaran Gilbride - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKRachel Halkerston - Public Health England, Salisbury, UKJennifer Hill - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKDaniel Jenkin - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Daniel.Jenkin@ndm.ox.ac.ukLisa Stockdale - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKMarije K Verheul - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKPK Aley - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKBrian Angus - Nuffield Department of Medicine, University of Oxford, Oxford, UKDuncan Bellamy - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKEleanor Berrie - Clinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKSagida Bibi - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKMustapha Bittaye - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKM Carroll - Clinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKBreeze Cavell - Public Health England, Salisbury, UKElizabeth Clutterbuck - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKNick Edwards - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKAmy Flaxman - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKMichelle Fuskova - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKAR Gorringe - Public Health England, Salisbury, UKBassam Hallis - Public Health England, Salisbury, UKSimon Kerridge - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKAlison M Lawrie - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKAline Linder - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKXinxue Liu - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKMeera Madhavan - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKRebecca Makinson - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKJack Mellors - Public Health England, Salisbury, UKAngela M Minassian - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKML Moore - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKYama Mujadidi - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKEmma Plested - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKIan Poulton - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKMaheshi Ramasamy - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKHannah Robinson - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKCHRISTINE ROLLIERRinn Song - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKMD Snape - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKRichard Tarrant - Clinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKStephen Taylor - Public Health England, Salisbury, UKK Thomas - Public Health England, Salisbury, UKMerryn Voysey - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UKMarion E E Watson - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKDaniel Wright - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKA Douglas - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKCatherine Green - Clinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKAdrian V.S Hill - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKTeresa Lambe - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKSC Gilbert - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UKAndrew J. Pollard - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Andrew.Pollard@paediatrics.ox.ac.uk
- Publication Details
- Nature medicine, Vol.27(6), pp.1113-1113
- Publication Date
- 06/05/2021
- Identifiers
- 99618165302346; WOS:000647954500005
- Academic Unit
- School of Biosciences
- Language
- English
- Resource Type
- Journal article
Journal article
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Nature medicine, Vol.27(6), pp.1113-1113
06/05/2021
PMID: 33958800